A Pioneer Compilation on Ibrutinib Loaded Hybrid Nanoformulations for Different Types of Cancer

Ibrutinib, a first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, has made a breakthrough in the management of multiple hematologic malignancies, including CLL and MCL. However, problems like low water solubility, low bioavailability and side effects if administered through the system hinder its therapeutic use. Research progress in targeted nanoformulations offers some potential solutions to overcome these challenges. This review also pays attention to the different nanoformulations for targeted delivery systems of Ibrutinib and relates to the delivery system’s design, working principle, therapeutic effects, and clinical applications. For instance, polymeric nanoparticles, liposomes, dendrimers, and Self-Nano Emulsifying Drug Delivery Systems (SNEDDS) that are prepared from Ibrutinib improved its bioavailability, toxicity, pharmacokinetics, and pharmacodynamics. Also, through targeting ligands on nano-carriers, selective delivery of Ibrutinib is enabled, this translates into increased effectiveness when used for eradicating targeted malignant cells and the least impact on normal cells hence reduced side effects. This review also presents other current clinical trials and patents supportive of the promise and efficacy of these nanoformulations in enhancing Ibrutinib treatment. These innovations not only bring high benefits to improve patient satisfaction but also a great opportunity to optimize the delivery systems of oncology drugs.